These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 30904510)
1. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510 [TBL] [Abstract][Full Text] [Related]
2. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. North EJ; Newman JD Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559 [TBL] [Abstract][Full Text] [Related]
3. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708 [TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918 [TBL] [Abstract][Full Text] [Related]
6. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes]. Scheen AJ Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058 [TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. Choxi R; Roy S; Stamatouli A; Mayer SB; Jovin IS Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):187-199. PubMed ID: 32306789 [No Abstract] [Full Text] [Related]
8. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
10. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes? Packer M Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741 [No Abstract] [Full Text] [Related]
11. GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease. Morrison L; Gabison J; Oshman L J Am Board Fam Med; 2024; 37(3):372-382. PubMed ID: 39142859 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Sharma A; Verma S Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322 [TBL] [Abstract][Full Text] [Related]
13. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. Tanaka A; Node K Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Scheen AJ Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes. Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101 [No Abstract] [Full Text] [Related]
16. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Fadah K; Alashi A; Deoker A Curr Cardiol Rep; 2022 Jan; 24(1):17-22. PubMed ID: 35000149 [TBL] [Abstract][Full Text] [Related]
17. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. Neves JS; Borges-Canha M; Vasques-Nóvoa F; Green JB; Leiter LA; Granger CB; Carvalho D; Leite-Moreira A; Hernandez AF; Del Prato S; McMurray JJV; Ferreira JP J Am Coll Cardiol; 2023 Aug; 82(6):517-525. PubMed ID: 37532422 [TBL] [Abstract][Full Text] [Related]
18. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor? Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123 [TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878 [TBL] [Abstract][Full Text] [Related]
20. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Lim S; Kim KM; Nauck MA Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]